difficulty of enrolling patients

To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.

Inclusion Criteria:

• ≥ 18 years;
• CACG (Chronic Angle Closure Glaucoma) ≥ 1eye
• have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the screening visit and IOP=19-32 mmHg (millimeters mercury) in at least one eye and ≤ 32 mmHg in both eyes
• clinical stability of VA (Visual Acuity) and optic nerve throughout the study

Exclusion Criteria:

• Abnormality restricts exam of the fundus or anderior chamber
• conjunctivitis, keratitis or uveitis
• unable to be discontinued from using all ocular hypotensive medication(s) except Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days-4weeks
• ocular surgery prior to the study